A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer

Abstract

NCT01301560.

The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer

“…SRS followed by chemotherapy in NSCLC with brain metastases resulted in a median OS of 14.6 months, similar to the 15.3 months reported for chemotherapy alone in a study by Lim et al, with the SRS arm reporting lower central nervous system (CNS) symptomatic progression rates than the chemotherapy alone arm (18.4% vs 26.5%) [6]. Rades et al showed that SRS had a local control rate of P75% in brain metastases [51].…”

“…Median OS of more than 12 months has been reported in a series of patients treated with this technique [6,7]. Molecularly targeted therapies including epidermal growth factor receptor (EGFR) inhibitors and anaplastic lymphoma kinase (ALK) inhibitors are being evaluated for the treatment of brain metastases in molecularly selected NSCLC patients, with initial reports of a median survival time around 12 months [5].…”

Guidelines for the treatment of central nervous system metastases using radiosurgery

“…Treatment with radiosurgery was well tolerated and there was no difference in neurocognitive function between the two study groups. 16 (A) Even when the tumor is located in critical areas, radiosurgery is feasible. Luther et al observed that motor function improves by 31% or remains stable in 50% of patients with brain metastases located in the motor cortex treated with radiosurgery.…”

State of the art of chemotherapy for the treatment of central nervous system metastases from non-small cell lung cancer

“…Lim et al randomized 105 patients with NSCLC and less than 4 BMs to receive SRS followed by a platinum-based doublet or a platinum-based doublet alone (68). Although the study included a smaller sample size than initially anticipated due to early termination, SRS followed by chemotherapy did not improve OS compared with upfront chemotherapy (median OS was 14.6 and 15.3 months in the SRS arm and upfront chemotherapy arm, respectively).…”